Use of recombinant factor VIIA plus continuous infusion of recombinant factor VIII in the hemostasis of type 3 von Willebrand disease with anaphylactic anti-VWF inhibitor

被引：0
|
作者：
Suzuki, N. [1 ]
Sanda, N. [2 ]
Matsushita, T. [3 ]
Kojima, T. [4 ]
Yamamoto, K. [3 ]
Katsumi, A. [5 ]
Hirashima, K. [1 ]
Kajiura, Y. [2 ]
Takatsu, M. [2 ]
Naoe, T. [1 ]
机构：
[1] Nagoya Univ Hosp, Nagoya, Aichi, Japan
[2] Nagoya Univ Hosp, Dept Clin Lab, Nagoya, Aichi, Japan
[3] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan
[4] Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Nagoya, Aichi 4648601, Japan
[5] Natl Ctr Geriatr & Gerontol, Dept Haematol, Tokyo, Japan
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-WE-459
引用
收藏
页码：665 / 665
页数：1
相关论文
共 50 条
  • [41] Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations
    Rastegar-Lari, G
    Ajzenberg, N
    Ribba, AS
    Vereycken-Holler, V
    Legendre, P
    Villoutreix, BO
    Meyer, D
    Baruch, D
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (06) : 1459 - 1465
  • [42] The challenging management of a child with type 3 von Willebrand disease (VWD) and antibodies to von Willebrand factor (VWF)
    Platokouki, H.
    Pergantou, H.
    Xafaki, P.
    Adamtziki, E.
    HAEMOPHILIA, 2012, 18 : 44 - 44
  • [43] Successful treatment of severe menorrhagia at menarche with recombinant factor VIIa in an adolescent girl with type III von Willebrand's disease
    Gokcebay, Dilek Gurlek
    Culha, Vildan
    Yarali, Nese
    Ozbek, Namik Yasar
    BLOOD COAGULATION & FIBRINOLYSIS, 2018, 29 (05) : 469 - 471
  • [44] Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - a rebuttal
    Sallah, S
    Isaksen, M
    Seremetis, S
    Rojkjaer, LP
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (04) : 820 - 822
  • [45] Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease
    Baronciani, L.
    Federici, A. B.
    Cozzi, G.
    Canciani, M. T.
    Mannucci, P. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (02) : 282 - 288
  • [46] Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor (vol 4, pg 762, 1998)
    Montoro, JB
    Altisent, C
    Pico, M
    Cabañas, MJ
    Vila, M
    Puig, LL
    HAEMOPHILIA, 1999, 5 (05) : 371 - 371
  • [47] Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient
    Rosenfeld, SB
    Watkinson, KK
    Thompson, BH
    Macfarlane, DE
    Lentz, SR
    THROMBOSIS AND HAEMOSTASIS, 2002, 87 (05) : 925 - 926
  • [48] PROPHYLAXIS WITH RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE: PHASE 3 TRIAL RESULTS
    Leebeek, Frank W. G.
    Peyvandi, Flora
    Escobar, Miguel
    Tiede, Andreas
    Castaman, Giancarlo
    Gu, Joan
    Mellgard, Bjorn
    Ewenstein, Bruce
    Ozen, Gulden
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E62 - E63
  • [49] Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
    Leebeek, Frank W. G.
    Peyvandi, Flora
    Escobar, Miguel
    Tiede, Andreas
    Castaman, Giancarlo
    Wang, Michael
    Wynn, Tung
    Baptista, Jovanna
    Wang, Yi
    Zhang, Jingmei
    Mellgard, Bjorn
    Ozen, Gulden
    BLOOD, 2022, 140 (02) : 89 - 98
  • [50] PROPHYLAXIS WITH RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE: POST HOC ANALYSIS FROM A PHASE 3 TRIAL
    Leebeek, Frank W. G.
    Escobar, Miguel
    Tiede, Andreas
    Wang, Michael
    Zulfikar, Bulent
    Wang, Scarlett
    Wang, Yi
    Ozen, Gulden
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E63 - E63
12345